Dizal Pharmaceutical (688192.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 3.639 billion yuan.

Zhitong Finance APP News, Dizal Pharmaceutical (688192.SH) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 4.77 billion yuan, a year-on-year increase of 713.50%. Net profit attributable to shareholders of the listed company was 3.639 billion yuan, and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 3.612 billion yuan.